-
APASL 2023 | Prof. George Lau: Seeking the “Cure” for Liver Disease – A Hepatologist’s Thirty-Year Journey of Exploration
Editor’s Note: The 32nd annual meeting of the Asia-Pacific Association for the Study of the Liver (APASL) was held at the Taipei International Convention Center in Taiwan, China, from February…
-
APASL 2023 | Prof. Ning Qin: Treatment of ACLF with Infection and Its Impact on Liver Transplantation
Editor’s Note: Acute-on-chronic liver failure (ACLF) refers to a syndrome where, on the basis of chronic liver disease, the patient experiences a rapid deterioration of liver function within a short…
-
ASCO China Voice | Breaking Survival Records: Avapritinib Combined with Azacitidine Achieves Median Overall Survival of 29.3 Months in Unfit AML!
From June 2nd to 6th, 2023, the American Society of Clinical Oncology (ASCO) Annual Meeting took place in a grand hybrid format in Chicago. ASCO Annual Meeting stands as one of the world’s largest, academically esteemed, and most authoritative international conferences in oncology. Encompassing cutting-edge advancements in all sub-specialties of oncology, the event attracts the…
-
Year-End Review | Professor Jianxiang Wang: Targeted New Drugs Lead the Wave of Advances in AML Treatment, Immunotherapy Also on the Rise!
Acute Myeloid Leukemia (AML) is a malignant clonal disease originating from hematopoietic stem cells. Affected myeloid cells (leukemic cells) undergo uncontrolled proliferation, differentiation disorders, and blocked apoptosis, accumulating in the bone marrow and other hematopoietic tissues. This inhibits normal hematopoietic function and infiltrates organs such as lymph nodes, liver, and spleen, leading to clinical features…
-
APASL 2023 | Prof. Ning Qin: New Strategies for Targeting Liver Autophagy Abnormalities in Fatty Liver Disease Interventions
Editor’s Note: In recent years, the global incidence of Non-Alcoholic Fatty Liver Disease (NAFLD) has been continuously rising, becoming the most common cause of chronic liver disease worldwide, with an…
-
APASL 2023 | Prof. Wu Chao: Metabolic Predictors and Liver Fibrosis Diagnostic Model Construction for Chronic Hepatitis B Combined with NAFLD
Editor’s Note: Chronic hepatitis B (CHB) is the primary cause of chronic liver disease in China and other Asian countries, as well as a major contributor to liver-related morbidity and…
-
APASL 2023 | Prof. Hou Jinlin: The New Hepatitis B Drug ALG-000184 Combined with Entecavir Shows Stronger Antiviral Activity Than Entecavir Alone
Editor’s Note: Chronic hepatitis B virus (HBV) infection is a global epidemic, yet we still lack a treatment that can completely conquer HBV. At present, most patients still need long-term…
-
Dr. Lai Wei talk about the Renaming of NAFLD to MASLD, Exploration of the Hepatitis B Research Paradigm, and Highlights from the 2023 EASL Congress
Dr. Lai Wei talk about the Renaming of NAFLD to MASLD, Exploration of the Hepatitis B Research Paradigm, and Highlights from the 2023 EASL Congress Dr. Lai Wei is a Professor of Hepatology & Medicine, and is the Director of the Hepatobiliary and Pancreatic Center at Beijing Tsinghua Changgung Hospital. His current research interests involve…
Connecting Medical Expertise through Media